Please assess the completion status of the following clinical trial:

Trial Title: ARFI, VisR and DDAI Ultrasound for Improving Discrimination of Malignant and Unresponsive Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~-~Aim 1:~Inclusion Criteria:~* Patients are 30-90 years of age~* Patients have breast masses with BIRADS 4a, 4b, 4c, or 5 rating~* Lesion is sonographically visible with B-Mode ultrasound on diagnostic workup~* Informed consent obtained and signed~Aim 2:~Inclusion Criteria:~* Patients are 30-90 years~* Patients who are or will be undergoing neoadjuvant chemotherapy (NAC) for stage 2 or 3 malignant breast lesions~* Lesion is sonographically visible with B-Mode ultrasound on diagnostic workup~* Informed consent is obtained and signed~Exclusion Criteria: Subjects who meet any of the exclusion criteria will be excluded from study participation for both Aim 1 and Aim 2.~* Inability to provide informed consent~* Inability to communicate in English~* Inability to remain motionless for 15 minutes~* Suspicious or malignant breast mass deeper than 3 cm from skin surface~* Previous biopsy or surgery to the site of the suspicious or malignant mass~* Patients who are pregnant~* Patients who are lactating~* Patients with a history of masectomy~* Patients with breast implants

- Gender: FEMALE
- Minimum Age: 30 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Women scheduled for biopsy (Type: None): 40 participants with diagnosed BIRADS-4a, 4b, 4c, or -5 masses will be recruited. The investigators aim to have approximately 10 in each of the BIRADS categories (4a, 4b, 4c, 5), resulting in 40 total subjects for Aim #1.
- Women scheduled for neoadjuvant chemo (Type: None): 40 participants with malignant masses undergoing neoadjuvant chemotherapy (NAC) will be recruited.

Based on this trial design, predict the completion outcome and termination type (if applicable).